Literature DB >> 20920709

Heparin-binding epidermal growth factor-like growth factor overexpression in transgenic mice increases resistance to necrotizing enterocolitis.

Andrei Radulescu1, Hong-Yi Zhang, Xiaoyi Yu, Jacob K Olson, Amanda K Darbyshire, Yan Chen, Gail E Besner.   

Abstract

BACKGROUND: Necrotizing enterocolitis (NEC) is the most common gastrointestinal emergency and the leading surgical cause of death in premature infants. We have shown that administration of exogenous heparin-binding epidermal growth factor-like growth factor (HB-EGF) in mice protects the intestines from experimental NEC. The aim of the current study was to evaluate the effect of gain-of-function of endogenous HB-EGF on susceptibility to NEC.
METHODS: Neonatal HB-EGF transgenic (TG) mice and their wild-type (WT) counterparts were exposed to experimental NEC. An additional group of HB-EGF TG pups were also exposed to NEC, but received the HB-EGF antagonist cross-reacting material 197 (CRM197) injected subcutaneously immediately after birth. To examine gut barrier function, HB-EGF TG and WT pups received intragastric fluorescein isothiocyanate-labeled dextran under basal and stressed conditions, and serum fluorescein isothiocyanate-labeled dextran levels were measured.
RESULTS: Wild-type mice had an incidence of NEC of 54.2%, whereas HB-EGF TG mice had a significantly decreased incidence of NEC of 22.7% (P = .03). Importantly, administration of CRM197 to HB-EGF TG pups significantly increased the incidence of NEC to 65% (P = .004). HB-EGF TG mice had significantly decreased intestinal permeability compared to WT mice both under basal and stressed conditions.
CONCLUSIONS: Our results provide evidence that overexpression of the HB-EGF gene decreases susceptibility to NEC and that administration of the HB-EGF antagonist CRM197 reverses this protective effect.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20920709      PMCID: PMC2953427          DOI: 10.1016/j.jpedsurg.2010.05.002

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  39 in total

1.  Isolation and characterization of a macrophage-derived heparin-binding growth factor.

Authors:  G Besner; S Higashiyama; M Klagsbrun
Journal:  Cell Regul       Date:  1990-10

2.  Effects of enteral and parenteral nutrition on gut mucosal permeability in the critically ill.

Authors:  R J Hadfield; D G Sinclair; P E Houldsworth; T W Evans
Journal:  Am J Respir Crit Care Med       Date:  1995-11       Impact factor: 21.405

3.  Production of heparin-binding epidermal growth factor-like growth factor (HB-EGF) at sites of thermal injury in pediatric patients.

Authors:  D W McCarthy; M T Downing; D R Brigstock; M H Luquette; K D Brown; M S Abad; G E Besner
Journal:  J Invest Dermatol       Date:  1996-01       Impact factor: 8.551

4.  Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity.

Authors:  T Mitamura; S Higashiyama; N Taniguchi; M Klagsbrun; E Mekada
Journal:  J Biol Chem       Date:  1995-01-20       Impact factor: 5.157

5.  Bifidobacterial supplementation reduces the incidence of necrotizing enterocolitis in a neonatal rat model.

Authors:  M S Caplan; R Miller-Catchpole; S Kaup; T Russell; M Lickerman; M Amer; Y Xiao; R Thomson
Journal:  Gastroenterology       Date:  1999-09       Impact factor: 22.682

6.  Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor.

Authors:  J G Naglich; J E Metherall; D W Russell; L Eidels
Journal:  Cell       Date:  1992-06-12       Impact factor: 41.582

7.  A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF.

Authors:  S Higashiyama; J A Abraham; J Miller; J C Fiddes; M Klagsbrun
Journal:  Science       Date:  1991-02-22       Impact factor: 47.728

8.  Role of asphyxia and feeding in a neonatal rat model of necrotizing enterocolitis.

Authors:  M S Caplan; E Hedlund; L Adler; W Hsueh
Journal:  Pediatr Pathol       Date:  1994 Nov-Dec

9.  Heparin-binding EGF-like growth factor: characterization of rat and mouse cDNA clones, protein domain conservation across species, and transcript expression in tissues.

Authors:  J A Abraham; D Damm; A Bajardi; J Miller; M Klagsbrun; R A Ezekowitz
Journal:  Biochem Biophys Res Commun       Date:  1993-01-15       Impact factor: 3.575

10.  Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity.

Authors:  R Iwamoto; S Higashiyama; T Mitamura; N Taniguchi; M Klagsbrun; E Mekada
Journal:  EMBO J       Date:  1994-05-15       Impact factor: 11.598

View more
  24 in total

1.  Early maternal separation induces alterations of colonic epithelial permeability and morphology.

Authors:  Bo Li; Carol Lee; Augusto Zani; Elke Zani-Ruttenstock; Wan Ip; Lijun Chi; Paul Delgado Olguin; Tanja Gonska; Agostino Pierro
Journal:  Pediatr Surg Int       Date:  2014-10-31       Impact factor: 1.827

2.  Heparin-binding EGF-like growth factor promotes neuronal nitric oxide synthase expression and protects the enteric nervous system after necrotizing enterocolitis.

Authors:  Yu Zhou; Yijie Wang; Jacob Olson; Jixin Yang; Gail E Besner
Journal:  Pediatr Res       Date:  2017-05-24       Impact factor: 3.756

3.  Heparin-binding epidermal growth factor-like growth factor and mesenchymal stem cells act synergistically to prevent experimental necrotizing enterocolitis.

Authors:  Jixin Yang; Daniel Watkins; Chun-Liang Chen; Bharath Bhushan; Yu Zhou; Gail E Besner
Journal:  J Am Coll Surg       Date:  2012-07-21       Impact factor: 6.113

4.  Heparin-binding epidermal growth factor-like growth factor improves intestinal barrier function and reduces mortality in a murine model of peritonitis.

Authors:  Jixin Yang; Andrei Radulescu; Chun-Liang Chen; Hong-Yi Zhang; Iyore O James; Gail E Besner
Journal:  Surgery       Date:  2012-06-15       Impact factor: 3.982

5.  Formula feeding and systemic hypoxia synergistically induce intestinal hypoxia in experimental necrotizing enterocolitis.

Authors:  Y Chen; Y Koike; H Miyake; B Li; C Lee; A Hock; A Zani; A Pierro
Journal:  Pediatr Surg Int       Date:  2016-11-04       Impact factor: 1.827

6.  Argininosuccinate lyase in enterocytes protects from development of necrotizing enterocolitis.

Authors:  M H Premkumar; G Sule; S C Nagamani; S Chakkalakal; A Nordin; M Jain; M Z Ruan; T Bertin; B Dawson; J Zhang; D Schady; N S Bryan; P M Campeau; A Erez; B Lee
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-06-05       Impact factor: 4.052

7.  M1 to M2 macrophage polarization in heparin-binding epidermal growth factor-like growth factor therapy for necrotizing enterocolitis.

Authors:  Jia Wei; Gail E Besner
Journal:  J Surg Res       Date:  2015-03-18       Impact factor: 2.192

Review 8.  The role of growth factors in intestinal regeneration and repair in necrotizing enterocolitis.

Authors:  Kathryn J Rowland; Pamela M Choi; Brad W Warner
Journal:  Semin Pediatr Surg       Date:  2013-05       Impact factor: 2.754

9.  The ErbB4 ligand neuregulin-4 protects against experimental necrotizing enterocolitis.

Authors:  Steven J McElroy; Shannon L Castle; Jessica K Bernard; Dana Almohazey; Catherine J Hunter; Brandon A Bell; Denise Al Alam; Larry Wang; Henri R Ford; Mark R Frey
Journal:  Am J Pathol       Date:  2014-09-09       Impact factor: 4.307

10.  Heparin-binding EGF-like growth factor (HB-EGF) therapy for intestinal injury: Application and future prospects.

Authors:  Jixin Yang; Yanwei Su; Yu Zhou; Gail E Besner
Journal:  Pathophysiology       Date:  2013-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.